{"name":"Exscientia AI Limited","slug":"exscientia-ai-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZjE1bWtOamFfbEgyYnQyZHNqTXR1bTBNRnRMRGtYdXNNSGc1VEswV2Z1VjNIc2dfelNpbnJvamFWcWhucVI1S0xEQldabEx3VVBrMWdKaTFGYUhWNFRsOGN4Yi1jS1dMWnlIeEN1UjBIaGNvUWh5NmhyYkZ1WXVINGR2S0lJUEE?oc=5","date":"2025-10-20","type":"deal","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed? - Yahoo Finance","headline":"Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Chang","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQblZoUXNTdVU2MUIxS2Zndm1CWjZWd3hyU0xXcWVacGpPVXhkazl0bElnbDczQlRYb3Z4VzEtSnhkWWd5QnZDWUgxNkIxQXFVZWlFcXk5QWlXMXJkOTFmS29sR1FSMnRQeE5qOW5nQWphZVNzNHFJOURiVi1oa2pWMzU1OA?oc=5","date":"2025-09-11","type":"pipeline","source":"pharmaphorum","summary":"The AI drug discovery race: Who’s leading the charge? - pharmaphorum","headline":"The AI drug discovery race: Who’s leading the charge?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOMHA4am1TSDVuUS15YkQ5N1ZnRkFpMV91X245Q29GMDVzTThjeFJCc0E0TVJyZTd0VWduaVhqT3hRTTE3OUN3SGh6U1ZMa3RTdFhhUzZQQ1RvZTFTblhVUjR6TXpsdDlzQ2FackdIcVRtMFU5Rm5NSmdsb3dQbV9odGlya25QZHBNbjBuR2IxT1FaNkox?oc=5","date":"2025-08-01","type":"pipeline","source":"Klover.ai","summary":"CSL’s AI Strategy: Analysis of Dominance in Biotechnology, Biopharma AI - Klover.ai","headline":"CSL’s AI Strategy: Analysis of Dominance in Biotechnology, Biopharma AI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPTFdhekxZd2k4cWVOWjNaU0Y3bWtsbWlqNkNxY3RYUnFVMC04ZmJCZDVFMzhNOUlZb3dGZEhYdTNrSWs5MmItT0ZrZVVKQ1VJOHJqNy1VV09rODdFRnROaXk1UjBGZTVXNnctWnYtUmVKQU0xSU04UGVEdFZ6T1loNk1KTF9McFFYZmYwTmwyMElsX2FySzRRWjZNalVUNHVjRXJxVGZReUUwbmxWYUlnZ3FB?oc=5","date":"2025-05-05","type":"deal","source":"fiercebiotech.com","summary":"Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline - fiercebiotech.com","headline":"Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBkQkZDTGlsdWtlSnAwNTBVbzZIVDJwcnZGeER2eHRLNGQxT3kzS1FhbzNVcEJfaXdwb3ozLUx1NmpEYU5WZWRfdTNxRkNuRmVKYjVF?oc=5","date":"2025-05-05","type":"pipeline","source":"FirstWord Pharma","summary":"Recursion's homegrown assets hardest hit in AI-discovered pipeline cull - FirstWord Pharma","headline":"Recursion's homegrown assets hardest hit in AI-discovered pipeline cull","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPampXRUpsTHNGNWJVVmtFdk1lc2RudzBzV3N0akhoRm51dmluc0dEdW9KRWwzampvZ1QwVXEtVXNadmFhX19IS2YzMEk1ZkN2Q2J0U200bUY2Ym1mZEMyWkVxV2lyVXNueS00YVI5eEZVZXlNX3BoNHJKQmpFOWQyN1psX1pyTm0tSDhHaEZPaGQ5NG1JQW1ZTTMxcTF0eXQ0OFZQRTRiMGdVU2pkeno1MDJQakFEWXFqUC1IT1B2Q3F5NUtjb0JIbUZXai1NOWs?oc=5","date":"2025-05-05","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus - Genetic Engineering and Biotechnology News","headline":"Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE11RFlnMERhTk5QVW1wZXNQSXRRM2x3UndBaFc3TXdlVXI2WmhkZE9EWnVUODNqcjdEeXl1UFlxN2haM1d4dkYwVUdEQS1LemEySVBTdnpFMGV2NHBPMmFObFVwcWp6RkQ4d296ekVzcjdaZC11?oc=5","date":"2025-03-27","type":"pipeline","source":"Labiotech.eu","summary":"12 AI drug discovery companies you need to watch in 2025 - Labiotech.eu","headline":"12 AI drug discovery companies you need to watch in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNZV90SXRuYUNMWVJCM1ZySm5keDlwRHJzMUUzd0NEc2R0UDc1U1ZwQUZwaW9IVUNRNnY5cjJYcE1aMUJJX2Job3liaGtxX3A0ZzhjX0NaWERjTHRMbVdVZzZjemdxZGYwSWF6TmNYOE4ydVlWUnlLQWRHWG54ZVBDb2lkMC02RzBp?oc=5","date":"2025-02-27","type":"deal","source":"Pharma Voice","summary":"AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration - Pharma Voice","headline":"AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNVFVyN0V6TXQyNU5aUEdSUVFibVZPOGhmbV9hRmphREdldmpYZ0x0QUlJSklYR24wTVppeFhJOFNHbVJzdXNZSlJZZjBRNG9zUjBaTFBRUDJqOFVEaVNXcHE1SzdFSlhudUMyLXlDbTRWU0pzb1NWLWh0UWYzbG9NN191M0pFdHpFSVFxWnNCaGlSYVJ0b0Rnbk9xako5dFZHeDVsd2sxcmdCTXdNUWc?oc=5","date":"2024-11-26","type":"deal","source":"statnews.com","summary":"Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger - statnews.com","headline":"Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQd292dXVhak1SMzZzZ3ZSNW14MTRuQk5EN3NTVlBJbWZvU0VOeE80VWhHcjBCRXR1a2szbEdhdUtMSkdOYnktVXBDazlMOTlGZVFZQTYta0RLSVpoWGc5QzVDbVo1MG1JV0FZb05VaEotYzNUQlNSd0JzdEpWWU0tTUxnWTM3WjBocjh0aHN3?oc=5","date":"2021-09-13","type":"pipeline","source":"SEC.gov","summary":"tm2119783-5_f1.htm - SEC.gov","headline":"tm2119783-5_f1.htm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPZ0hsWjJ1UnZfYzNLTmZObVV0MmxObjFHbTVGYVk3NktnLVNFMU5IWjRGUy1sc1dpaHhHUlg2V1hpMXhVYWVGNDFFR1RxSGVQOWdoMkwtbGVCbUVRSms5NXhXQ1V0SF93eElMSzJuTHNwMjgzYVA0QmJCb2JOS0lGRGVaUQ?oc=5","date":"2021-05-20","type":"deal","source":"Pharmaceutical Technology","summary":"Exscientia signs $1.2bn AI drug discovery deal with BMS - Pharmaceutical Technology","headline":"Exscientia signs $1.2bn AI drug discovery deal with BMS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNd3dORlV5SmVZSUNHRnZRalE2bjlPU1o2RVVFU0ZRYllaQ0d5dUM4b3FOX2dTR245Y1ptRmlSUW03YUtuX3pYaERRZ1BWQUlkTm45TWZyazliWWxnbjZYcko4SURPSmJGbGhxTVFneG9HTzhnaGdFTW5kTF9Semh1UE5fckhLS3BaRnNUUDNrRk9CM0RERnNKTFdfa205UVNrZi1xN0hsQUR6RWNz?oc=5","date":"2021-05-14","type":"pipeline","source":"PharmaTimes","summary":"Alzheimer’s drug designed using Exscientia’s AI technology enters clinic - PharmaTimes","headline":"Alzheimer’s drug designed using Exscientia’s AI technology enters clinic","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}